A prediction model for left ventricular thrombus persistence/recurrence: based on a prospective study and a retrospective study.

"Declarations Ethics approval and consent to participateThe study protocols were approved by the Ethics Committees of Fuwai Hospital (prospective study: approval No. 2020–1380; retrospective study: approval No. 2022–1757) with written informed consent in the prospective study and oral informed consent in the retrospective study. Consent for publicationNot applicable. Competing interestsThe authors declare no competing interests. Competing interests The authors declare no competing interests."

"Funding This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors."

"This study was derived from two studies, including a prospective study named R-DISSOLVE (ClinicalTrials.gov: NCT04970381) and a retrospective registry study (ClinicalTrials.gov: NCT 05,006,677), carried out at Fuwai Hospital, National Center of Cardiovascular Diseases in China. R-DISSOLVE was an interventional, single-arm, open-label, investigator-initiated study between October 2020 and April 2022. The retrospective study collected data from June 2013 to December 2019 by using electronic medical records. The two study protocols were developed separately and approved by the ethics committee at the participating center. The combined study was reported in accordance with the TRIPOD checklist []."